Literature DB >> 21389155

Comparison of strain typing results for Clostridium difficile isolates from North America.

Fred C Tenover1, Thomas Akerlund, Dale N Gerding, Richard V Goering, Therése Boström, Anna-Maria Jonsson, Edith Wong, Alan T Wortman, David H Persing.   

Abstract

Accurate strain typing is critical for understanding the changing epidemiology of Clostridium difficile infections. We typed 350 isolates of toxigenic C. difficile from 2008 to 2009 from seven laboratories in the United States and Canada. Typing was performed by PCR-ribotyping, pulsed-field gel electrophoresis (PFGE), and restriction endonuclease analysis (REA) of whole-cell DNA. The Cepheid Xpert C. difficile test for presumptive identification of 027/NAP1/BI isolates was also tested directly on original stool samples. Of 350 isolates, 244 (70%) were known PCR ribotypes, 224 (68%) were 1 of 8 common REA groups, and 187 (54%) were known PFGE types. Eighty-four isolates typed as 027, NAP1, and BI, and 83 of these were identified as presumptive 027/NAP1/BI by Xpert C. difficile. Eight additional isolates were called presumptive 027/NAP1/BI by Xpert C. difficile, of which three were ribotype 027. Five PCR ribotypes contained multiple REA groups, and three North American pulsed-field (NAP) profiles contained both multiple REA groups and PCR ribotypes. There was modest concordance of results among the three methods for C. difficile strains, including the J strain (ribotype 001 and PFGE NAP2), the toxin A-negative 017 strain (PFGE NAP9 and REA type CF), the 078 animal strain (PFGE NAP7 and REA type BK), and type 106 (PFGE NAP11 and REA type DH). PCR-ribotyping, REA, and PFGE provide different but overlapping patterns of strain clustering. Unlike the other methods, the Xpert C. difficile 027/NAP1/BI assay gave results directly from stool specimens, required only 45 min to complete, but was limited to detection of a single strain type.

Entities:  

Mesh:

Year:  2011        PMID: 21389155      PMCID: PMC3122689          DOI: 10.1128/JCM.02446-10

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  46 in total

1.  Increased sporulation rate of epidemic Clostridium difficile Type 027/NAP1.

Authors:  Thomas Akerlund; Ingela Persson; Magnus Unemo; Torbjörn Norén; Bo Svenungsson; Marlene Wullt; Lars G Burman
Journal:  J Clin Microbiol       Date:  2008-02-20       Impact factor: 5.948

Review 2.  Clostridium difficile--more difficult than ever.

Authors:  Ciarán P Kelly; J Thomas LaMont
Journal:  N Engl J Med       Date:  2008-10-30       Impact factor: 91.245

3.  Clostridium difficile toxinotype V, ribotype 078, in animals and humans.

Authors:  Maja Rupnik; Andreas Widmer; Ortrud Zimmermann; Catherine Eckert; Frédéric Barbut
Journal:  J Clin Microbiol       Date:  2008-04-16       Impact factor: 5.948

4.  Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078.

Authors:  Abraham Goorhuis; Dennis Bakker; Jeroen Corver; Sylvia B Debast; Celine Harmanus; Daan W Notermans; Aldert A Bergwerff; Frido W Dekker; Ed J Kuijper
Journal:  Clin Infect Dis       Date:  2008-11-01       Impact factor: 9.079

5.  National point prevalence of Clostridium difficile in US health care facility inpatients, 2008.

Authors:  William R Jarvis; JoAnn Schlosser; Ashley A Jarvis; Raymond Y Chinn
Journal:  Am J Infect Control       Date:  2009-03-10       Impact factor: 2.918

6.  Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008.

Authors:  E J Kuijper; F Barbut; J S Brazier; N Kleinkauf; T Eckmanns; M L Lambert; D Drudy; F Fitzpatrick; C Wiuff; D J Brown; J E Coia; H Pituch; P Reichert; J Even; J Mossong; A F Widmer; K E Olsen; F Allerberger; D W Notermans; M Delmée; B Coignard; M Wilcox; B Patel; R Frei; E Nagy; E Bouza; M Marin; T Akerlund; A Virolainen-Julkunen; O Lyytikäinen; S Kotila; A Ingebretsen; B Smyth; P Rooney; I R Poxton; D L Monnet
Journal:  Euro Surveill       Date:  2008-07-31

7.  Clostridium difficile ribotypes 027 and 106: clinical outcomes and risk factors.

Authors:  F Sundram; A Guyot; I Carboo; S Green; M Lilaonitkul; A Scourfield
Journal:  J Hosp Infect       Date:  2009-04-21       Impact factor: 3.926

8.  Characterization of Clostridium difficile strains isolated from patients in Ontario, Canada, from 2004 to 2006.

Authors:  H Martin; B Willey; D E Low; H R Staempfli; A McGeer; P Boerlin; M Mulvey; J S Weese
Journal:  J Clin Microbiol       Date:  2008-07-23       Impact factor: 5.948

9.  Toxinotype V Clostridium difficile in humans and food animals.

Authors:  Michael A Jhung; Angela D Thompson; George E Killgore; Walter E Zukowski; Glenn Songer; Michael Warny; Stuart Johnson; Dale N Gerding; L Clifford McDonald; Brandi M Limbago
Journal:  Emerg Infect Dis       Date:  2008-07       Impact factor: 6.883

10.  A confidence interval for the wallace coefficient of concordance and its application to microbial typing methods.

Authors:  Francisco R Pinto; José Melo-Cristino; Mário Ramirez
Journal:  PLoS One       Date:  2008-11-11       Impact factor: 3.240

View more
  34 in total

1.  Detection of toxigenic Clostridium difficile: comparison of the cell culture neutralization, Xpert C. difficile, Xpert C. difficile/Epi, and Illumigene C. difficile assays.

Authors:  P Pancholi; C Kelly; M Raczkowski; J M Balada-Llasat
Journal:  J Clin Microbiol       Date:  2012-01-25       Impact factor: 5.948

2.  Is fidaxomicin worth the cost? An economic analysis.

Authors:  Sarah M Bartsch; Craig A Umscheid; Neil Fishman; Bruce Y Lee
Journal:  Clin Infect Dis       Date:  2013-05-23       Impact factor: 9.079

3.  Differences in the Molecular Epidemiology and Antibiotic Susceptibility of Clostridium difficile Isolates in Pediatric and Adult Patients.

Authors:  Larry K Kociolek; Dale N Gerding; James R Osmolski; Sameer J Patel; David R Snydman; Laura A McDermott; David W Hecht
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

4.  Presumptive identification of Clostridium difficile strain 027/NAP1/BI on Cepheid Xpert: interpret with caution.

Authors:  Jen Kok; Qinning Wang; Lee C Thomas; Gwendolyn L Gilbert
Journal:  J Clin Microbiol       Date:  2011-08-17       Impact factor: 5.948

5.  Prevalence and risk factors for asymptomatic Clostridium difficile carriage.

Authors:  Faisal Alasmari; Sondra M Seiler; Tiffany Hink; Carey-Ann D Burnham; Erik R Dubberke
Journal:  Clin Infect Dis       Date:  2014-04-21       Impact factor: 9.079

6.  Evaluation of cycloserine-cefoxitin fructose agar (CCFA), CCFA with horse blood and taurocholate, and cycloserine-cefoxitin mannitol broth with taurocholate and lysozyme for recovery of Clostridium difficile isolates from fecal samples.

Authors:  Kerin L Tyrrell; Diane M Citron; Eliza S Leoncio; C Vreni Merriam; Ellie J C Goldstein
Journal:  J Clin Microbiol       Date:  2013-06-26       Impact factor: 5.948

7.  Strain types and antimicrobial resistance patterns of Clostridium difficile isolates from the United States, 2011 to 2013.

Authors:  Isabella A Tickler; Richard V Goering; Joseph D Whitmore; Ashley N W Lynn; David H Persing; Fred C Tenover
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

8.  Comparative genomics analysis of Clostridium difficile epidemic strain DH/NAP11/106.

Authors:  Larry K Kociolek; Dale N Gerding; David W Hecht; Egon A Ozer
Journal:  Microbes Infect       Date:  2018-01-31       Impact factor: 2.700

Review 9.  Clostridium difficile infection: epidemiology, diagnosis and understanding transmission.

Authors:  Jessica S H Martin; Tanya M Monaghan; Mark H Wilcox
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-03-09       Impact factor: 46.802

10.  In the Endemic Setting, Clostridium difficile Ribotype 027 Is Virulent But Not Hypervirulent.

Authors:  Samuel L Aitken; M Jahangir Alam; Mohammed Khaleduzzaman; Mohammed Khaleduzzuman; Seth T Walk; William L Musick; Vy P Pham; Jennifer L Christensen; Robert L Atmar; Yang Xie; Kevin W Garey
Journal:  Infect Control Hosp Epidemiol       Date:  2015-08-20       Impact factor: 3.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.